This document is a publication of a European patent application (EP4630118A1) by Idorsia Pharmaceuticals Ltd. It details a specific crystalline adipic acid salt form of a CCR6 antagonist, along with its intended therapeutic applications, particularly in treating conditions classified under A61P 35/00 (Antineoplastics). The publication includes inventor names and International Patent Classification codes.

This patent publication does not impose new regulatory obligations on companies. It serves as a notification of intellectual property protection sought for a specific pharmaceutical compound. Compliance officers in the pharmaceutical sector should note this publication as it relates to the patent landscape for CCR6 antagonists, which may impact future research, development, and commercialization strategies.